Industry landscapes
The companies, capital and talent shaping healthtech in Seattle. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
21 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
No company example met every recorded classification, independence and public-profile gate in this snapshot. The live directory may have newer qualifying companies.
Explore classified startups in Radar ↗A few useful ratios bring the size of this ecosystem into perspective.
24 of 290 tracked companies have open roles.
116 of 290 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 318 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 38.9% of disclosed capital, while 60.0% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $106.01M | 18 | 19 |
| 2017 | $111.43M | 18 | 25 |
| 2018 | $211.48M | 19 | 23 |
| 2019 | $208.02M | 14 | 22 |
| 2020 | $444.77M | 19 | 25 |
| 2021 | $811.58M | 18 | 28 |
| 2022 | $333.25M | 6 | 22 |
| 2023 | $374.72M | 13 | 18 |
| 2024 | $21.65M | 4 | 10 |
| 2025 | $464.48M | 3 | 20 |
Share of all disclosed company funding.
346 recorded rounds since 2016
Recorded participation in healthtech company rounds since 2016.
Backed by .
Backed by Equal Opportunity Ventures and Talipot and others.
Backed by Hudson Bay Capital and Lux Capital and others.
Backed by Regeneron Pharmaceuticals and Trinity Health and others.
Backed by Rock Springs Capital and Viking Global Investors and others.
Backed by Insight Partners and General Atlantic and others.
Backed by Goldman Sachs and L Catterton and others.
Backed by Viking Global Investors.
Backed by RA Capital Management and The D. E. Shaw Group and others.
Backed by CVS Health.
Backed by Scott Barclay and Dragoneer Investment Group and others.
Participating investors were not recorded in this snapshot.
Annual accounts for reporting companies linked to this landscape, on like-for-like currency and reporting bases.
Display conversions use the dated reference rates above. Where a verified rate is unavailable, figures retain their source currency. Each reporting cohort keeps its currency and accounting basis separate.
FY2025 · company accounts; aggregate reporting threshold not met · 1 reporting entities from 4 eligible matches.
Sum of reporting-entity revenue; not Seattle market sales.
Combined result for the same cohort.
Combined net income ÷ combined revenue.
The middle covered reporting entity.
None of 1 covered entities.
Share of covered revenue from the five largest entities.
Reported cohort totals by year; coverage is stated for every period.
Bar height shows revenue. Changes in coverage can affect totals.
FY2025 · 1 reporting entities
Up to eight fixed company previews show financial amounts. Search and sort the wider company list, then continue in Radar.
| Company / reporting entity | Revenue | Net profit / loss | Net margin | Revenue growth | Total assets |
|---|---|---|---|---|---|
| Adaptive Biotechnologies ↗1478320 | $277.0m | $-59.5m | -21.5% | — | — |
Explore full company accounts and filings.
Choose “View accounts” to inspect an available company preview.
Each pair uses the same year, currency and reporting basis. Cohort overlap is disclosed.
| Industry | Covered / eligible | Revenue total | Median revenue | Net profit / loss | Aggregate margin | Profitable share | Overlap |
|---|
Available-account cohorts are not estimates of whole industries. Overlapping entities can occur in more than one cohort; do not add cohort totals.
Filed annual accounts for exact designated national identifiers. Every aggregate and peer pair uses one fiscal year, source currency and reporting basis; periods, coverage and overlap are explicit; 2026 partials are excluded.
The same up to eight reporting entities remain open across years, filters and sorts. Other company figures are available in Radar.
Source currencies and accounting bases stay separate. Missing accounts are excluded rather than treated as zero. Exact reporting periods appear on company previews. Annual totals can change with coverage and do not measure growth of a fixed company cohort.
How the Seattle companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
32 of these companies (11%) publish at least one Android app — 38 apps in all, carrying 1.3M installs between them.
| App | Installs | Rating | Store category |
|---|---|---|---|
| Carby HealthCarbon Health | 454.2K | 4 | Medical |
| MYIOValant | 315.6K | 4.8 | Medical |
| FitnessSyncerFitnessSyncer | 178.7K | 2.5 | Health & Fitness |
| ModentoModento | 139K | 3.4 | Medical |
| Mobilize powered by FavoriteFavorite Healthcare Staffing | 75.4K | 2.5 | Productivity |
| Brook+HealthSlate | 20.2K | 3.2 | Health & Fitness |
| MindbloomMindbloom | 19.6K | 4.7 | Health & Fitness |
| Brook Health CompanionBrook | 15.8K | 3.7 | Health & Fitness |
| PreemptiveAIPreemptiveAI | 8.5K | 3.5 | Medical |
| Oryx CamOryx Dental | 8.2K | — | Medical |
Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.
The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2023Q1–2026Q1).
| Segment | Apps | Installs | Leading app | Release trend |
|---|---|---|---|---|
| Healthcare It | 28 | 749.8K | MYIO 315.6K | |
| Healthcare Booking Platforms | 4 | 480.7K | Carby Health 454.2K | |
| Disease Self Management | 6 | 38.4K | Brook+ 20.2K | |
| Artificial Intelligence | 2 | 8.5K | PreemptiveAI 8.5K | |
| Wearable Technology | 3 | 1.7K | Remmie (Legacy) 715 |
A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.
New apps published, beside apps whose most recent update landed in that quarter — the second bar is how much of the shelf is still being maintained.
Darker bars are new releases, lighter bars apps updated. 37 of 38 apps carry a release date. The series ends at 2026Q1, the last quarter that closed before the June 2026 reading.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
14 companies hiring · $2.91B disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
Zocalo Health, a Kenmore, Wash.-based primary care provider designed for high-need populations, raised $15 million in Series A funding.
The North Texas Angel Network invested $125,000 in Glidance Inc. in 2025, among several deals the Richardson-based group made during an active year.
In support of the proceedings, Future Solutions Investments has committed to provide up to $19.5 million in debtor-in-possession (DIP) financing.
Seattle-based mental health startup Joon Care has been acquired by Handspring Health, a New York-based health tech company.
MDI, a leading Insurtech company specializing in cloud-based core system solutions for life, health, annuity insurance, and risk management sectors, has acquired the Vendor Cost Control (VCC) software from JDI Data to transform construction defect cost management.
Pear Suite, a digital health company empowering community health workers (CHWs), today announced that it has raised $7.6 million in Series A funding to advance the development of its AI-powered platform, fuel its provider network growth, and expand its impact through new Medicaid and Medicare health plan contracts.
Private equity firm Pencarrow and iwi investor Ahuahu Group have invested an undisclosed amount in primary healthcare provider Tend Health.
The funding round was led by DeepTech and life sciences investment group EMV Capital and totals £1.9m.
Samsung Electronics said on Tuesday it had signed an agreement to acquire Xealth, a U.S.-based healthcare platform, as part of its efforts to expand its mobile healthcare services business.
CueZen, an AI-based personalization engine for health, today announced a $5 million in funding led by Point72 Ventures, with participation from Pack VC, Fortson VC, and Nextinfinity.
Top 10 categories among 144 recorded events in the 24-month window.
1 companies with recorded IPO activity
IPO · NASDAQ1 reports
6 tracked people moves
Appointment Chief Marketing Officer
Appointment Chief Technology Officer
Appointment Chief Product Officer
Appointment Chief People Officer
Retirement Previously Chief Financial Officer
Appointment Chief Financial Officer
1 recorded customer wins
Customer: National Institutes of Health (NIH)
1 companies with reported reductions
Scale not stated roleseconomic pressures
5 recorded events
plan acceptedNYSE American
approved for tradingNYSE Regulation
symbol \'D\' temporarily allotted for 20 daysFINRA
approved to quote on OTCQBOTC Markets Group Inc.
4 tracked suits
contract services payment for nine monthsCivil · Settled
tax deduction for foreign dividendsCivil · Settled
Reported company results in the recorded window.
Median across 35 reported growth observations; companies may contribute multiple periods.
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| handspring health→Joon ↗ | Completed | 2026-01-29 | Not stated in snapshot |
| samsung→Xealth ↗ | Completed | 2025-12-01 | Not stated in snapshot |
| MDI→jdi data | Announced | 2025-11-05 | Not stated in snapshot |
| Calypso Medical Technologies→Boston Scientific Corp | Announced | 2025-02-14 | $90.0M |
| Calypso Medical Technologies→ACCEL Instruments | Completed | 2025-02-14 | $30.0M |
| Bruker Advanced Supercon→Calypso Medical Technologies ↗ | Completed | 2025-02-14 | Not stated in snapshot |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
841 postings in the preceding 12 months. The full 1,295-posting snapshot covers 39 employers.
22 tracked postings mention remote work.
290 postings specify a level.
Top skills across 1,295 tracked postings in the available jobs snapshot.
Median across 117 postings with pay data, expressed in USD.
| Company | Employees |
|---|---|
| virginia mason medical center ↗ | 4,671 |
| Carbon Health ↗ | 1,194 |
| Adaptive Biotechnologies ↗ | 609 |
| MCG Health ↗ | 585 |
| Truveta ↗ | 250 |
| RealSelf ↗ | 211 |
| CorneaGen ↗ | 205 |
| Impel NeuroPharma ↗ | 158 |
201 founders and chief executives across 131 companies.
Carbon Health, ex-Z Gallerie, ex-Rixos Transportation, University of Arizona, 2007
Ex-Microsoft, Ramco Systems. National Institute of Technology Warangal MTech 1995, The Wharton School MBA 2010
Life Science Washington, ex-Aortica, ex-American Heart Association, University of Pennsylvania - The Wharton School, 2002
98point6, ex-Quellos, University of Washington, 1984
Providence Digital Innovation Group, C-SATS, Intuitive Surgical, Snowden Pencer. United States Naval Academy BS
A Place For Mom, ex-American Express, ex-Comcast, Harvard Business School, 2016
University Of Washington, ex-University Of Wisconsin Madison, ex-Tasso, University of Wisconsin-Madison, 2011
Proprio, ex-Washington Biotechnology And Biomedical Association, ex-Intentional Futures…
ex-President & CEO SightLife, Washington Global Health Alliance. ASU BS 1992, Duke University MBA 2003
Ex-Central Washington University, Kalytera Therapeutics, biOasis Technologies Inc., eCharge Corporation.University of Wyoming M.A 1968…
Ex -Founder Sema4, Sage Bionetworks, Pacific Biosciences. Icahn School of Medicine at Mount Sinai B.S, University of California MA 1993, UCLA PhD1999
Co-Founder Xealth, ex-Providence Health & Services, Nuance Communications, CEO Swype, Co-Founder Amp'd Mobile, Boost Mobile & Zivo Internet Services…
31 profiles with education records.
14 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
17,232 articles in the measured 12-month window.
Healthtech coverage tagged Seattle · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 3,710 |
| 2021Q3 | 3,821 |
| 2021Q4 | 3,172 |
| 2022Q1 | 3,830 |
| 2022Q2 | 3,702 |
| 2022Q3 | 3,372 |
| 2022Q4 | 3,457 |
| 2023Q1 | 3,601 |
| 2023Q2 | 3,753 |
| 2023Q3 | 3,608 |
| 2023Q4 | 3,932 |
| 2024Q1 | 4,126 |
| 2024Q2 | 3,738 |
| 2024Q3 | 3,796 |
| 2024Q4 | 3,635 |
| 2025Q1 | 9,259 |
| 2025Q2 | 4,295 |
| 2025Q3 | 5,258 |
| 2025Q4 | 3,566 |
| 2026Q1 | 3,892 |
Article volume measures coverage, not market sales.
196 recorded company events across 33 companies; percentages use that event total.
Healthtech coverage tagged Seattle · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
United States comparison coverage
| Keyword | Recent | Prior | Change |
|---|---|---|---|
| foreign policy analysis | 7,248 | 4,848 | 50% |
| multilateral diplomacy | 7,093 | 4,378 | 62% |
| national security strategy | 7,075 | 3,119 | 127% |
| bilateral trade | 5,915 | 4,221 | 40% |
| diplomatic engagements | 5,572 | 3,522 | 58% |
| vaccine candidates | 5,445 | 1,402 | 288% |
| vaccine trials | 4,931 | 1,374 | 259% |
| vaccination campaigns | 4,914 | 1,021 | 381% |
| countries | 4,204 | 1,897 | 122% |
| vaccine immunogenicity | 4,034 | 1,074 | 276% |
| olympic team selections | 1,407 | 2,836 | -50% |
| olympic trials | 1,103 | 2,360 | -53% |
| ceasefire violations | 903 | 1,703 | -47% |
| summer olympics athletics | 209 | 1,564 | -87% |
| electioneering tactics | 665 | 1,562 | -57% |
United States comparison coverage
territories, disputed islands, vaccine mandate compliance
42.5% critical · 22.3% positivepublic health funding, investment deal, inflation reports fx
46.9% critical · 41.2% positiveearnings report, quarterly results, quarterly financials
35.3% critical · 45.4% positiveHealthtech coverage tagged Seattle. Topic labels describe recorded classifications and can include broad context.
8,843 papers in the recorded india scope.
Tone counts: 7,674 positive · 337 neutral · 832 negative.
Landmark: Implementation strategies: recommendations for specifying and reporting
Landmark: Realist synthesis: illustrating the method for implementation research
Landmark: Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science
Common problems researchers identify · 0118.0% of this theme group
Researchers highlight obstacles in developing effective pharmaceuticals and navigating pharmacogenomic complexities.
Drug discovery (305) · Drug (169) · Pharmacogenomics (141) · Drug development (96)
Cancer epigenetics drug discovery and development: the challenge of hitting the mark
Proof of Concept: Network and Systems Biology Approaches Aid in the Discovery of Potent Anticancer Drug Combinations
| Year | Share index |
|---|---|
| 2022 | 155.8 |
| 2023 | 160.7 |
| 2024 | 168.0 |
| 2025 | 209.7 |
Common problems researchers identify · 0218.0% of this theme group
Studies point to equity and participation issues limiting telemedicine reach for diverse patient groups.
Telemedicine (687) · Telehealth (648) · Health care (347) · Nursing (98)
Ensuring full participation of people with disabilities in an era of telehealth
Strategies for Evaluating Telehealth
| Year | Share index |
|---|---|
| 2022 | 541.2 |
| 2023 | 553.5 |
| 2024 | 538.6 |
| 2025 | 840.0 |
Common problems researchers identify · 0313.6% of this theme group
Analyses reveal difficulties in aligning administration, nursing, and informatics for coordinated chronic care.
Health administration (209) · Nursing research (154) · Health informatics (234) · Public health (215)
Is Europe putting theory into practice? A qualitative study of the level of self-management support in chronic care management approaches
Understanding integrated service delivery: a scoping review of models for noncommunicable disease and mental health interventions in low-and
| Year | Share index |
|---|---|
| 2022 | 22.0 |
| 2023 | 20.3 |
| 2024 | 26.9 |
| 2025 | 43.6 |
Common problems researchers identify · 0413.6% of this theme group
Works discuss hurdles in applying personalized approaches to cancer subtyping and treatment.
Precision medicine (602) · Personalized medicine (282) · Cancer (105) · Disease (121)
The growing role of precision and personalized medicine for cancer treatment
Precision Medicine: Disease Subtyping and Tailored Treatment
| Year | Share index |
|---|---|
| 2022 | 764.3 |
| 2023 | 1049.9 |
| 2024 | 798.6 |
| 2025 | 777.4 |
Common problems researchers identify · 0513.5% of this theme group
Authors examine challenges of embedding digital tools within broader health system frameworks.
Digital health (431) · Health care (328) · Health informatics (149) · Informatics (73)
Technology and Universal Health Coverage: Examining the role of digital health
Digital Health and Health Systems of the Future
| Year | Share index |
|---|---|
| 2022 | 540.1 |
| 2023 | 553.1 |
| 2024 | 540.7 |
| 2025 | 849.1 |
Common problems researchers identify · 0613.1% of this theme group
Research flags inequalities and sustainability questions arising from COVID‑19 telehealth expansion.
Pandemic (570) · Coronavirus disease 2019 (384) · 2019-20 coronavirus outbreak (108) · Telemedicine (386)
Telemedicine and health access inequalities during the COVID-19 pandemic
Examining telehealth use among primary care patients, providers, and clinics during the COVID-19 pandemic
| Year | Share index |
|---|---|
| 2022 | 661.4 |
| 2023 | 443.9 |
| 2024 | 330.0 |
| 2025 | 212.6 |
Common problems researchers identify · 0710.3% of this theme group
Papers stress the need for robust standards and usability testing for interoperable devices.
Medical device (152) · Wearable computer (47) · Health care (152) · Food and drug administration (36)
The Need to Apply Medical Device Informatics in Developing Standards for Safe Interoperable Medical Systems
Medical Device Usability Analyses
| Year | Share index |
|---|---|
| 2022 | 564.5 |
| 2023 | 577.8 |
| 2024 | 564.0 |
| 2025 | 876.1 |
Cautions · 0124.5% of this theme group
Evidence suggests careful evaluation of home telehealth’s effectiveness and cost before broad adoption.
Telemedicine (394) · Telehealth (307) · Medical emergency (63) · Health care (134)
Home telehealth for chronic disease management: A systematic review and an analysis of economic evaluations
Transition to telehealth
| Year | Share index |
|---|---|
| 2022 | 215.3 |
| 2023 | 197.2 |
| 2024 | 209.5 |
| 2025 | 199.0 |
Cautions · 0215.8% of this theme group
Studies warn of implementation challenges and data governance issues in digital health initiatives.
Health informatics (124) · Health administration (73) · Nursing research (49) · Health care (117)
A systematic approach to the planning, implementation, monitoring, and evaluation of integrated health services
INFORMATION SYSTEMS IN HEALTH MANAGEMENT: INNOVATIONS AND CHALLENGES IN THE DIGITAL ERA
| Year | Share index |
|---|---|
| 2022 | 22.0 |
| 2023 | 20.3 |
| 2024 | 26.9 |
| 2025 | 43.6 |
Cautions · 0315.4% of this theme group
Research highlights patient and clinician hesitancy affecting telemedicine uptake during health crises.
Pandemic (268) · Coronavirus disease 2019 (208) · Telemedicine (212) · Telehealth (177)
Patient Perception of Telehealth Services for Breast and Gynecologic Oncology Care during the COVID-19 Pandemic: A Single Center Survey-base
Community Mental Health Clinicians’ Perspectives on Telehealth During the COVID-19 Pandemic: Mixed Methods Study
| Year | Share index |
|---|---|
| 2022 | 548.5 |
| 2023 | 379.1 |
| 2024 | 244.3 |
| 2025 | 190.4 |
Cautions · 0414.4% of this theme group
Analyses point to limited evidence and variability in applying genetic testing to drug therapy.
Pharmacogenomics (86) · Drug discovery (91) · Drug (59) · Pharmacology (33)
Pharmacogenomic Testing and Depressive Symptom Remission: A Systematic Review and <scp>Meta‐Analysis</scp> of Prospective, Controlled Clinic
Warfarin Pharmacogenomics in Diverse Populations
| Year | Share index |
|---|---|
| 2022 | 155.8 |
| 2023 | 160.7 |
| 2024 | 168.0 |
| 2025 | 209.7 |
Cautions · 0511.4% of this theme group
Authors discuss efficacy gaps and ethical concerns surrounding technology‑based psychological treatments.
Psychological intervention (118) · Digital health (104) · Mental health (62) · Intervention (56)
Digital Health Interventions to Enhance Prevention in Primary Care: Scoping Review
Digitization and its Discontents: The Promise and Limitations of Digital Mental Health Interventions
| Year | Share index |
|---|---|
| 2022 | 784.7 |
| 2023 | 800.0 |
| 2024 | 802.5 |
| 2025 | 1143.3 |
Cautions · 0611.3% of this theme group
Papers caution that many targeted therapies lack robust clinical validation across cancer types.
Precision medicine (127) · Personalized medicine (61) · Cancer (49) · Oncology (37)
Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials
Mechanism-Centric Approaches for Biomarker Detection and Precision Therapeutics in Cancer
| Year | Share index |
|---|---|
| 2022 | 764.3 |
| 2023 | 1049.9 |
| 2024 | 798.6 |
| 2025 | 777.4 |
Cautions · 077.1% of this theme group
Research raises concerns about data bias and interpretability when using AI for treatment decisions.
Applications of artificial intelligence (19) · Health care (53) · Precision medicine (36) · Personalized medicine (28)
Leveraging Artificial Intelligence for Predictive Healthcare: A Data-Driven Approach to Early Diagnosis and Personalized Treatment
Advancements in the treatment of autoimmune diseases: Integrating artificial intelligence for personalized medicine
| Year | Share index |
|---|---|
| 2022 | 543.5 |
| 2023 | 558.4 |
| 2024 | 545.5 |
| 2025 | 874.8 |
Opportunities · 0118.5% of this theme group
Studies explore how remote care can improve access and engagement for older adults.
Telehealth (669) · Telemedicine (567) · Pandemic (136) · Coronavirus disease 2019 (120)
Urgent and non-emergent telehealth care for seniors: Findings from a multi-site impact study
Using inpatient telehealth for family engagement: A mixed methods study of perceptions from patients, families, and care team providers
| Year | Share index |
|---|---|
| 2022 | 548.9 |
| 2023 | 380.0 |
| 2024 | 246.2 |
| 2025 | 194.7 |
Opportunities · 0216.2% of this theme group
Works showcase in‑silico methods accelerating discovery and optimization of novel therapeutics.
Drug discovery (597) · Computational biology (310) · Chemical space (104) · Drug (199)
Assessing molecular docking tools: understanding drug discovery and design
Landscape of <i>In Silico</i> Tools for Modeling Covalent Modification of Proteins: A Review on Computational Covalent Drug Discovery
| Year | Share index |
|---|---|
| 2022 | 182.1 |
| 2023 | 196.4 |
| 2024 | 225.2 |
| 2025 | 259.1 |
Opportunities · 0315.8% of this theme group
Research proposes frameworks for cohesive digital interventions addressing population health needs.
Digital health (225) · Health informatics (198) · Health care (254) · Public health (106)
IDEAS (Integrate, Design, Assess, and Share): A Framework and Toolkit of Strategies for the Development of More Effective Digital Interventi
Integrated Digital Mental Health Care: A Vision for Addressing Population Mental Health Needs
| Year | Share index |
|---|---|
| 2022 | 540.1 |
| 2023 | 553.1 |
| 2024 | 540.7 |
| 2025 | 849.1 |
Opportunities · 0415.7% of this theme group
Papers present emerging compounds and pathways with promising therapeutic activity in living models.
Drug discovery (269) · Drug (133) · Pharmacology (64) · In vivo (56)
Development and Characterization of Selective FAK Inhibitors and PROTACs with <i>In Vivo</i> Activity
A kinase to cytokine explorer to identify molecular regulators and potential therapeutic opportunities
| Year | Share index |
|---|---|
| 2022 | 512.3 |
| 2023 | 527.8 |
| 2024 | 495.0 |
| 2025 | 494.4 |
Opportunities · 0513.1% of this theme group
Studies highlight rapid genomic profiling to guide tailored treatments in breast tumor management.
Cancer (230) · Precision medicine (278) · Oncology (89) · Breast cancer (91)
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
Systems approach for congruence and selection of cancer models towards precision medicine
| Year | Share index |
|---|---|
| 2022 | 893.2 |
| 2023 | 1222.6 |
| 2024 | 953.9 |
| 2025 | 908.7 |
Opportunities · 0611.3% of this theme group
Research demonstrates phenome‑wide approaches to refine disease classification and therapeutic stratification.
Precision medicine (299) · Personalized medicine (212) · Disease (137) · Health care (84)
Phenome-Wide Association Studies as a Tool to Advance Precision Medicine
Precision medicine in complex diseases—Molecular subgrouping for improved prediction and treatment stratification
| Year | Share index |
|---|---|
| 2022 | 1258.8 |
| 2023 | 1116.7 |
| 2024 | 1011.1 |
| 2025 | 1302.9 |
Opportunities · 079.4% of this theme group
Works describe remote monitoring and surgical robotics advancing patient care and real‑time data capture.
Wearable computer (90) · Remote patient monitoring (52) · Surgical robot (38) · Robot (36)
Development of a remote therapeutic monitoring platform: applications for movement disorders
IoT-enabled health monitoring system for real time patient care: Design and evaluation
| Year | Share index |
|---|---|
| 2022 | 32.7 |
| 2023 | 34.5 |
| 2024 | 35.7 |
| 2025 | 61.7 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Problem-identifying | 32.5% | 9.9% |
| Promising | 29.8% | 37.2% |
| Descriptive | 14.9% | 17.5% |
| Breakthrough | 11.9% | 26.1% |
| Cautionary | 7.3% | 4.6% |
| Comparative | 2.9% | 3.8% |
| Critical | 0.7% | 0.8% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceThe future of digital health with federated learning | 1,121 | 2.85% | 599 (53.4%) | 2.66% |
| Safety & misuseImpact of Rumors and Misinformation on COVID-19 in Social Media | 72 | 0.18% | 36 (50.0%) | 0.17% |
| Bias & fairnessPrivacy Protection, Personalized Medicine, and Genetic Testing | 29 | 0.07% | 16 (55.2%) | 0.06% |
| Hardware, e-waste & supply chainToo many bits: tackling the waste epidemic in digital medicine | 4 | 0.01% | 1 (25.0%) | 0.01% |
| Concentration of compute powerDemonopolizing Medical Knowledge | 3 | 0.01% | 2 (66.7%) | 0.01% |
| Energy & datacenter footprintSUSTAINABLE GREEN COMPUTING FOR MEDICAL APPLICATIONS: ADVANCING RESPONSIBLE HEALTHCARE IT | 2 | 0.01% | 2 (100.0%) | 0.01% |
| Labour & data workLabor markets for health supply chain management in Rwanda: a qualitative study of stakeholder perspectives | 2 | 0.01% | 2 (100.0%) | 0.01% |
| Carbon & emissions of computePotential reduction in healthcare carbon footprint by autonomous artificial intelligence | 1 | 0.0% | 0 (0.0%) | 0.0% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
Institution and researcher rankings use citations to their covered work. Research scope: United States. This may be broader than the company geography.
Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 5 August 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗